MacroGenics to Participate in Upcoming Investor Conferences

Spread the love

newsdesk@globenewswire.com (NewsDesk)

ROCKVILLE, MD, Feb. 03, 2022 (GLOBE NEWSWIRE) — MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company’s management will participate in the following virtual conferences in February 2022.

Translate »

MacroGenics to Participate in Upcoming Investor Conferences

by Off Site Reports time to read: <1 min
0